Robert Driscoll
Stock Analyst at Wedbush
(3.05)
# 1,269
Out of 5,139 analysts
156
Total ratings
36.96%
Success rate
3.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $30 → $37 | $28.77 | +28.61% | 9 | Dec 16, 2025 | |
| CGON CG Oncology | Initiates: Outperform | $70 | $54.73 | +27.90% | 1 | Dec 11, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $25 → $34 | $10.72 | +217.16% | 5 | Dec 9, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $8.46 | +349.17% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $120.28 | -33.49% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $8.32 | +356.73% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $7.04 | +155.68% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $13.51 | +99.85% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $2.96 | +35.14% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.55 | +992.30% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $23.71 | -28.30% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $57 → $12 | $12.20 | -1.64% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $10.16 | +214.96% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $35.84 | +45.09% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.56 | +525.00% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $21.80 | +37.61% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $8.28 | +866.18% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.90 | +1,125.63% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $6.02 | +115.95% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $13.01 | -0.08% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $13.76 | +437.79% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.70 | +40.35% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.31 | +434.35% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $5.39 | +48.42% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.06 | -1.48% | 4 | May 19, 2020 |
Tyra Biosciences
Dec 16, 2025
Maintains: Outperform
Price Target: $30 → $37
Current: $28.77
Upside: +28.61%
CG Oncology
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $54.73
Upside: +27.90%
Cullinan Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $25 → $34
Current: $10.72
Upside: +217.16%
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $8.46
Upside: +349.17%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $120.28
Upside: -33.49%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $8.32
Upside: +356.73%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $7.04
Upside: +155.68%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $13.51
Upside: +99.85%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.96
Upside: +35.14%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.55
Upside: +992.30%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $23.71
Upside: -28.30%
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $12.20
Upside: -1.64%
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $10.16
Upside: +214.96%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $35.84
Upside: +45.09%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.56
Upside: +525.00%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $21.80
Upside: +37.61%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $8.28
Upside: +866.18%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.90
Upside: +1,125.63%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $6.02
Upside: +115.95%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $13.01
Upside: -0.08%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.76
Upside: +437.79%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.70
Upside: +40.35%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.31
Upside: +434.35%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $5.39
Upside: +48.42%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.06
Upside: -1.48%